A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease.

Shiri, Isaac; Abdollahi, Hamid; Atashzar, Mohammad Reza; Rahmim, Arman; Zaidi, Habib

Shiri, Isaac; Abdollahi, Hamid; Atashzar, Mohammad Reza; Rahmim, Arman; Zaidi, Habib.

Shiri I; Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.
Abdollahi H; Department of Radiologic Sciences and Medical Physics, Faculty of Allied Medicine, Kerman University of Medical Science, Kerman.
Atashzar MR; Department of Immunology, School of Medicine, Fasa University of Medical Science, Fasa, Iran.
Rahmim A; Departments of Radiology and Physics, University of British Columbia.
Zaidi H; Department of Integrative Oncology, BC Cancer Research Centre, Vancouver BC, Canada.

Nucl Med Commun ; 41(9): 837-840, 2020 09.

Article in English | MEDLINE | ID: covidwho-717256

Subject(s)

Antiviral Agents; CRISPR-Associated Proteins; Coronavirus Infections; Nuclear Medicine; Pandemics; Pneumonia, Viral; Betacoronavirus; COVID-19; Humans; Incidental Findings; Prevalence; SARS-CoV-2; Theranostic Nanomedicine

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Pandemics / CRISPR-Associated Proteins / Nuclear Medicine Type of study: Diagnostic study / Observational study Limits: Humans Language: English Journal: Nucl Med Commun Year: 2020 Document Type: Article Affiliation country: MNM.0000000000001269

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google